Jazz Pharmaceuticals raises $1.1 bn via exchangeable notes and launches concurrent share repurchases to strengthen its balance sheet and return capital
Executive summary: Jazz Pharmaceuticals priced $1.1 billion aggregate principal amount of 1.875 % exchangeable senior notes due 2032 and announced concurrent ordinary share repurchases. The transaction provides low‑cost debt financing, funds a shareholder return program, and reflects the company’s confidence in its ability to service the new obligations.
Who is involved: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and private placement investors participating in the offering.
Likely next: Proceeds will be used to refinance existing debt and fund the share repurchases; the notes will begin trading privately and may be exchanged for Jazz shares if the conversion price is exceeded.
The Irish‑drawn pharmaceutical company priced $1.1 billion of 1.875 % exchangeable senior notes maturing in 2032 in a private placement. At the same time it announced an ordinary share buy‑back program, using part of the proceeds to repurchase its own stock. The move refinances existing debt at a low coupon while signalling confidence in future cash flows to investors.
Timeline
- — Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases (PR Newswire)
Analysis — what this means
Sectors affected
- Pharmaceuticals
- Debt capital markets